Strattera vs Adderall: Key Differences | Forest Psychological Clinic

Strattera and Adderall can both be used to treat ADHD, but they are different kinds of medication. Strattera contains atomoxetine, a nonstimulant. Adderall contains mixed amphetamine salts, a stimulant, and comes in immediate-release tablets and extended-release capsules called Adderall XR. The formulation matters when discussing how the medication fits into a day (Eli Lilly and Company, 2026; Takeda Pharmaceuticals America, 2026; Teva Pharmaceuticals USA, 2024).

Choosing between them involves the person's age, health history, previous treatment response, and preferences. It also requires agreement about what improvement would look like. Being able to follow a conversation, finish an assignment, or manage the morning routine may matter more to someone than simply feeling more alert.

For medication details, review the MedlinePlus atomoxetine guide and the NICE ADHD medication recommendations.

At Forest Psychological Clinic, Patrick Lancaster, PMHNP, starts treatment plans, adds prescriptions when appropriate, and manages existing medication regimens. He considers current treatment, previous medication experiences, and what a patient or family is comfortable taking alongside the clinical evidence. That conversation can include a nonstimulant when it is clinically appropriate. Concerns about medication deserve a specific discussion of benefits, risks, and alternatives.

The main differences between Strattera and Adderall

The product labels establish formulation and controlled-substance distinctions. The American Academy of Child and Adolescent Psychiatry (AACAP) medication guide explains the difference between stimulant effects within hours and atomoxetine's more gradual response (AACAP, 2020; Eli Lilly and Company, 2026; Takeda Pharmaceuticals America, 2026; Teva Pharmaceuticals USA, 2024).

Strattera and Adderall XR are FDA approved for ADHD in adults and children ages 6 and older. The immediate-release Adderall tablet label includes pediatric use beginning at age 3. That distinction does not make it the recommended starting treatment for a preschooler. For ages 4 through 5, the American Academy of Pediatrics recommends parent training in behavior management and/or classroom behavioral intervention first, with methylphenidate considered in specified circumstances (Wolraich et al., 2019). Product approval and an individual treatment recommendation answer different questions.

What the research says about effectiveness

A 2018 review of 133 randomized trials found that amphetamines produced larger average reductions in clinician-rated ADHD symptoms than atomoxetine in short-term comparisons. When weighing effectiveness and tolerability together, the authors favored methylphenidate for children and adolescents and amphetamines for adults as initial short-term options (Cortese et al., 2018).

Those findings concern groups of patients and medication classes. The amphetamine category included multiple products, and network meta-analysis combines direct comparisons with indirect evidence across trials. It cannot tell an individual that Adderall will necessarily work better or be easier to tolerate.

A newer review covering 113 adult ADHD trials found short-term symptom benefits for both stimulants and atomoxetine on patient and clinician ratings. Confidence in those findings ranged from very low to moderate. Atomoxetine also had more discontinuation for any reason than placebo, and longer-term evidence remained limited (Ostinelli et al., 2025).

This supports considering both options while being specific about the tradeoffs. An average advantage in symptom scores does not resolve a person's experience of appetite loss, sleep disruption, or another adverse effect. A useful treatment must provide enough benefit to justify its burdens.

Give each medication an appropriate assessment period

Stimulants can produce noticeable effects within hours at an effective dose. For Adderall, it is useful to record when benefit begins and when it fades. An extended-release preparation may cover more of the day, but the actual pattern needs to be observed in that person (AACAP, 2020).

Atomoxetine requires a different expectation. Its benefit develops over weeks, so a few days without a clear change may be too early to judge it. Take it consistently as prescribed and agree on when to assess progress. The prescriber should consider the dose, time at that dose, benefit, and tolerability together (American Society of Health-System Pharmacists [ASHP], 2024).

Ask what improvement is reasonable to look for before the next visit and what would justify contacting the clinician sooner. Allowing time for benefit does not mean enduring troubling side effects until a scheduled appointment. Do not change the dose, combine medicines, or introduce medication breaks without an agreed plan.

Side effects and monitoring deserve equal attention

Patrick says the medication questions he hears most often concern side effects and whether treatment is helping the symptoms it is intended to address. Both belong in the follow-up conversation.

Stimulant side effects can include reduced appetite, difficulty sleeping, headache, stomach discomfort, and irritability. The FDA also emphasizes the risks of misuse, addiction, and overdose. Adderall should be stored securely and never shared (U.S. Food and Drug Administration [FDA], 2023).

Atomoxetine can cause nausea, reduced appetite, constipation, dry mouth, tiredness, and dizziness. Sexual side effects and difficulty urinating also deserve discussion, even if they feel awkward to mention (ASHP, 2024).

Both medications require attention to cardiovascular health. A 2025 review of 102 randomized trials found increases in blood pressure or pulse with several ADHD medicines, including atomoxetine and amphetamines. Its authors recommended monitoring across medication types. Most included trials were short, with a median follow-up of seven weeks, so the findings do not settle long-term cardiovascular risk (Farhat et al., 2025).

Before treatment, discuss personal and family heart history, current medicines, sleep, appetite, and mental health history. Follow-up should include relevant physical measurements, the person's own experience, and growth monitoring for children. NICE's ADHD guideline recommends monitoring effectiveness and adverse effects throughout treatment (National Institute for Health and Care Excellence [NICE], 2019).

Strattera carries a boxed warning about suicidal thoughts and behaviors in children and adolescents. Close observation is especially important early in treatment and around dose changes. Rare severe liver injury has also been reported. Adderall carries a boxed warning about abuse, misuse, and addiction; new psychotic or manic symptoms are another important concern (Eli Lilly and Company, 2026; Takeda Pharmaceuticals America, 2026).

Seek urgent medical help for chest pain, fainting, or serious breathing difficulty. Contact the treating clinician immediately about new suicidal thoughts, marked behavioral changes, hallucinations, or yellowing of the skin or eyes. If someone is in immediate danger, use emergency services. These examples are not a complete list of risks; review the medication guide and contact plan with the prescriber (ASHP, 2024; Teva Pharmaceuticals USA, 2024).

Anxiety and autism add context to the decision

An anxiety diagnosis does not automatically rule out stimulants or establish that atomoxetine is the better choice. NICE's UK guideline recommends offering the same ADHD medication choices to people with co-occurring anxiety or autism, while using slower dose adjustments and closer monitoring when relevant conditions are present (NICE, 2019).

Describe the anxiety itself and its timing. Was it present before medication? Does it emerge after a dose, during a difficult task, or when the medication appears to wear off? These observations help the clinician investigate what is happening. New or worsening distress should be reported without assuming that it will necessarily disappear.

For an autistic person with ADHD, identify the ADHD symptoms being targeted and the supports still needed. Sensory accommodations, predictable routines, and accessible communication can remain important parts of care. Dr. James Thatcher emphasizes understanding these needs when planning support. The medication decision should remain connected to the person's goals and experience.

Other medications can change the comparison

A complete medication list can alter which option makes sense. For example, fluoxetine and paroxetine can increase atomoxetine exposure by affecting the enzyme CYP2D6. Adderall has important interactions too, including the risk of serotonin syndrome, a potentially dangerous reaction, with certain other medicines. Both have restrictions involving monoamine oxidase inhibitors, or MAOIs (Eli Lilly and Company, 2026; Takeda Pharmaceuticals America, 2026).

Bring prescriptions, over-the-counter products, supplements, and previous medication records. Patrick specifically asks patients to bring a medication history so the discussion can account for what helped, what did not, and any prior reactions. Tell the prescriber about other medical conditions, pregnancy plans, or breastfeeding as well.

Explain what did not work before choosing the next step

Saying a medication “didn't work” can describe several experiences. There may have been little benefit, improvement for only part of the day, or meaningful benefit accompanied by unacceptable side effects. Bring the details that distinguish those situations.

Patrick describes reviewing response and tolerability when considering another medication. His interview also explains that people may respond differently to the two major stimulant classes, amphetamine and methylphenidate. A disappointing experience with one stimulant therefore leaves other options to discuss, including nonstimulants when appropriate. The next step is an individual clinical decision.

For instance, someone who can concentrate through the morning but struggles again in the afternoon has a different question from someone who feels persistently unwell after every dose. Recording the timing helps make that distinction. It does not mean either person should adjust the prescription independently.

Make follow-up useful

Patrick encourages brief notes about changes in daily functioning. Choose a few things that matter to you and record both benefit and unwanted effects. For a child, their own experience matters alongside observations from caregivers and, with appropriate permission, school staff.

Useful questions for the visit include:

• What specific difficulties are we trying to improve, and what has changed?

• Have I tried this medication long enough at the prescribed dose to assess it?

• Could the formulation or timing help explain the pattern I am noticing?

• Which side effects or health findings would lead us to reconsider the plan?

• How will I reach the prescribing team between appointments?

Dr. Thatcher describes medication and therapy as tools that can work together. Reduced interference from ADHD symptoms may make it easier to practice strategies, while therapy can address organizing tasks, procrastination, and other everyday difficulties. The plan should reflect the help that person needs.

Forest Psychological Clinic offers psychiatric medication management with Patrick Lancaster, PMHNP, alongside individual therapy. Whether you are considering medication for the first time or reviewing an existing plan, contact the clinic and describe your current concerns and treatment history. For children younger than six, ask about age-specific restrictions and whether Patrick's care is appropriate. An appointment provides an opportunity to discuss suitable options and a plan for reviewing their effects.

Strattera vs Adderall at a Glance

Strattera vs Adderall is a comparison between a non-stimulant ADHD medication and a stimulant medication. They differ in how quickly they tend to work, how they are scheduled, their side-effect profiles, and how clinicians monitor treatment.

How quickly do they work?

Adderall may produce noticeable effects on the day it is taken, while Strattera generally requires consistent daily use and time to evaluate. A slower onset does not necessarily mean a medication is less effective for the person taking it.

Why might a clinician consider Strattera?

A prescriber may discuss Strattera when stimulant side effects, misuse concerns, coexisting symptoms, medical history, or a preference for a non-stimulant option affect treatment planning.

Why might a clinician consider Adderall?

Adderall may be considered when a stimulant is appropriate and faster symptom coverage is a treatment priority. Medication selection still requires an individualized assessment and follow-up.

ADHD Treatment Resources

Learn who treats ADHD after diagnosis, review Forest’s ADHD evaluation service, or request medication management.

Want help comparing ADHD medication options?

A medication consultation can help you weigh potential benefits, side effects, and monitoring needs. Explore ADHD medication management at Forest Psychological Clinic.